LONDON – Oculis SA has cleared a path for its lead program OC-118 to become the first non-invasive treatment for diabetic macular edema (DME), raising CHF20 million (US$20.3 million) in a series B round that will enable the company to complete an ongoing phase IIb trial and file the IND for a U.S. phase III.